Epileptic seizure

Eisai Presents New Seizure Freedom and Adherence Data Related to Anti-Epileptic Drug FYCOMPA® at the 2019 American Epilepsy Society Annual Meeting

Retrieved on: 
Monday, December 9, 2019
Health, Medicine, Clinical medicine, Epilepsy, Perampanel, Epileptic seizure, Eisai, Anticonvulsant

WOODCLIFF LAKE, N.J., Dec. 9, 2019 /PRNewswire/ -- Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore.

Key Points: 
  • WOODCLIFF LAKE, N.J., Dec. 9, 2019 /PRNewswire/ -- Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore.
  • Of Eisai's 38 scientific posters about FYCOMPA, 23 included convulsive seizure freedom data underscoring Eisai's continued commitment to helping as many patients as possible achieve the ultimate goal of seizure freedom.
  • "This data provides important insights that we hope will help health care professionals as we work collectively toward the ultimate goal of seizure freedom."
  • Partial-onset seizures are the most common type of seizure seen in people with epilepsy, accounting for 60 percent of all seizures.

Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy

Retrieved on: 
Sunday, December 8, 2019
Health, Clinical trials, Research, Pharmaceutical, Science, Biotechnology, Medicine, Clinical medicine, Health, Epileptic seizure, RTT, Syndromes, GABAA receptor positive allosteric modulators, Epilepsy, Lactams, Epilepsy syndromes

The data are being presented today during a poster presentation session at the American Epilepsy Society (AES) 2019 Meeting in Baltimore.

Key Points: 
  • The data are being presented today during a poster presentation session at the American Epilepsy Society (AES) 2019 Meeting in Baltimore.
  • We look forward to advancing the clinical development program of CVL-865 as we proceed to a Phase 2 trial in patients with drug-resistant focal onset seizures.
  • CVL-865 is a novel 2/3/5-subtype selective GABAA receptor positive allosteric modulator.
  • Approximately 65 million people worldwide suffer from epilepsy, according to the Epilepsy Foundation, and it affects people of all ages.

Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

Retrieved on: 
Saturday, December 7, 2019
Biotechnology, Health, Stem cells, Pharmaceutical, Clinical trials, Branches of biology, Medicine, Clinical medicine, Dravet syndrome, Sodium channels, SCN1A, Electrophysiology, Nav1.1, Haploinsufficiency, Epilepsy, Epileptic seizure, Electroencephalography, STK-001, Dravet Syndrome, Stoke Therapeutics

EEG is a highly sensitive measure of seizure activity, which enables the detection of seizures that may not be otherwise visible.

Key Points: 
  • EEG is a highly sensitive measure of seizure activity, which enables the detection of seizures that may not be otherwise visible.
  • What is particularly remarkable is that these data were generated from a spontaneous seizure model, which we believe accurately reflects the clinical situation in people with Dravet syndrome.
  • Dravet syndrome is a severe and progressive genetic epilepsy that begins within the first year of life.
  • In the studies presented in todays poster, the efficacy of STK-001 was evaluated in a Scn1a-linked mouse model of Dravet syndrome that results in Nav1.1 haploinsufficiency.

Neurelis Announces Nine Poster Presentations At The Annual Meeting Of The American Epilepsy Society

Retrieved on: 
Thursday, December 5, 2019
Medicine, Clinical medicine, Health, Epileptic seizure, RTT, Epilepsy, Syndromes, Neurosurgical procedures

"During the ongoing clinicaldevelopment programof the investigational product VALTOCO, over 2,000 seizures have been treated,"said Craig Chambliss, President and CEO of Neurelis.

Key Points: 
  • "During the ongoing clinicaldevelopment programof the investigational product VALTOCO, over 2,000 seizures have been treated,"said Craig Chambliss, President and CEO of Neurelis.
  • "As a result, we have been able to accumulate a wealth of administration and safety data of VALTOCO use in epilepsy patients experiencing cluster seizures.
  • We are very pleased to be presenting nine posters at AES that supportthe rigorous science behind VALTOCO.
  • These presentations have been made possible by theoutstandingparticipation of our investigators, their dedicated staffand, most significantly, the patients who participated in these important studies."

Engage Therapeutics Announces Two Poster Presentations at the American Epilepsy Society’s Annual Meeting

Retrieved on: 
Wednesday, December 4, 2019
RTT, GABAA receptor positive allosteric modulators, Chloroarenes, Alprazolam, Anxiolytics, Triazolobenzodiazepines, Epileptic seizure

A Two-Part, Phase 2b Efficacy Study of Staccato Alprazolam Inhaler in Patients with Epilepsy with a Predictable Seizure Pattern: Results from Part 1 and Early Results from Part 2," Poster #: 1.310.

Key Points: 
  • A Two-Part, Phase 2b Efficacy Study of Staccato Alprazolam Inhaler in Patients with Epilepsy with a Predictable Seizure Pattern: Results from Part 1 and Early Results from Part 2," Poster #: 1.310.
  • A Phase 1 Open-Label, Single-Dose, Pharmacokinetic Study Evaluating Staccato Alprazolam 1 mg Inhaler in Smoker versus Non-Smoker Healthy Adult Participant, Poster #: 1.299.
  • Engage Therapeutics is developing Staccato alprazolam for the immediate termination of an ongoing epileptic seizure.
  • Engage Therapeutics is based in Summit, N.J. For additional information please see www.engagetherapeutics.com .

JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

Retrieved on: 
Monday, December 2, 2019
Neurological disorders, Organ systems, Health, Lennox–Gastaut syndrome, Dravet syndrome, Epilepsy, Anticonvulsant, Epileptic seizure, Stiripentol, Epilepsy-intellectual disability in females, Epilepsy syndromes

The study demonstrated that adding FINTEPLA to these patients treatment regimens led to a significant and clinically meaningful (> 50%) reduction in monthly convulsive seizure frequency (MCSF).

Key Points: 
  • The study demonstrated that adding FINTEPLA to these patients treatment regimens led to a significant and clinically meaningful (> 50%) reduction in monthly convulsive seizure frequency (MCSF).
  • Patients in the FINTEPLA arm also experienced longer seizure-free intervals, which is important as many were previously experiencing multiple seizures per week.
  • Study 1504 was an international, double-blind, placebo-controlled Phase 3 study of 87 Dravet syndrome patients age 2-19 taking background anti-epileptic drug regimens that included stiripentol, randomized to placebo (n=44) or FINTEPLA 0.4 mg/kg/day (n=43)*.
  • Zogenix expects top-line data from its Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome (LGS) in the first quarter of 2020.

Real-World Seizure Reduction Outcomes with the NeuroPace RNS System to be Presented at the American Epilepsy Society 2019 Annual Meeting

Retrieved on: 
Monday, December 2, 2019
Biotechnology, Medical devices, Health, Data management, Technology, Neurotechnology, Epilepsy, Medicine, Organ systems, Neuroprosthetics, Responsive neurostimulation device, Nervous system, Electrotherapy, Medical devices, Epileptic seizure, RNS, Neurostimulation, the RNS® System, NeuroPace

A key presentation will reveal new real-world seizure reduction outcomes achieved with the use of the companys RNS System.

Key Points: 
  • A key presentation will reveal new real-world seizure reduction outcomes achieved with the use of the companys RNS System.
  • Presenters will include:
    Martha Morrell, MD, PhD, Clinical Professor of Neurology at Stanford University and Chief Medical Officer of NeuroPace.
  • The RNS System is the worlds first and only closed-loop brain-responsive neurostimulation system designed to prevent epileptic seizures at their source.
  • The companys first product, the RNS System, is the only FDA-approved brain-responsive neurostimulator for the treatment of focal onset refractory epilepsy.

SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

Retrieved on: 
Wednesday, November 27, 2019
Health, Articles, Life sciences, Pharmaceutical industry, Epileptic seizure, RTT, Epilepsy, Biopharmaceutical, Food and Drug Administration, AED

We believe cenobamate could potentially be a welcome new treatment option for people living with this debilitating condition.

Key Points: 
  • We believe cenobamate could potentially be a welcome new treatment option for people living with this debilitating condition.
  • Further information can be found in the press release issued by SK Biopharmaceuticals and SK life science on November 21, 2019.
  • SK life science, based in Paramus, New Jersey, is pursuing clinical development and the U.S. commercialization of cenobamate.
  • Cenobamate was discovered by SK Biopharmaceuticals and SK life science and is a new FDA-approved anti-epileptic drug (AED) for the treatment of partial-onset seizures in adults.

UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.

Retrieved on: 
Monday, November 25, 2019
Medicine, Clinical medicine, Health, RTT, Rhinorrhea, Throat irritation, Adverse effect, Epileptic seizure

"For the first time, people 12 years and older now have a nasally administered rescue therapy shown to help manage seizure clusters.

Key Points: 
  • "For the first time, people 12 years and older now have a nasally administered rescue therapy shown to help manage seizure clusters.
  • NAZYILAM can be administered anywhere seizure clusters strike, allowing families to take back valuable moments that would otherwise be lost."
  • "An effective seizure cluster rescue treatment, like NAYZILAM, that is convenient and easily administered, along with a seizure cluster action plan, can change the lives of people living with seizure clusters and their families."
  • The most common adverse reactions (5% in any NAYZILAM treatment group) were somnolence, headache, nasal discomfort, throat irritation, and rhinorrhea.

FDA Approves XCOPRI® (cenobamate tablets), an Anti-Epileptic Drug (AED) from SK Biopharmaceuticals, Co., Ltd., and U.S. Subsidiary SK Life Science, Inc.

Retrieved on: 
Thursday, November 21, 2019
Health, Medicine, Clinical medicine, RTT, Anticonvulsants, Epileptic seizure, Epilepsy, Food and Drug Administration, Syndromes, Carisbamate, Responsive neurostimulation device

The FDA approval of XCOPRI for the treatment of partial-onset seizures is a welcome option for the epilepsy community."

Key Points: 
  • The FDA approval of XCOPRI for the treatment of partial-onset seizures is a welcome option for the epilepsy community."
  • The approval also marks the first time a Korean company has independently brought a compound from discovery to U.S. FDA approval.
  • XCOPRI was discovered and developed by SK Biopharmaceuticals and SK life science and is an FDA-approved anti-epileptic drug (AED) for the treatment of partial-onset seizures in adults.
  • SK life science, based in Paramus, New Jersey, is pursuing clinical development and the U.S. commercialization of XCOPRI.